Bruce Thompson, PhD serves as CEO at Kincell Bio. Prior to this role, Bruce was Vice President and Technical Lead for the Cell Therapy Franchise at Resilience, Inc., where he helped to build the development and GMP manufacturing capabilities and served as a technical advisor.
Bruce has significant experience in CMC strategy, product development and cell therapy manufacturing experience. As Vice President of Process Sciences at Lyell Immunopharma, he was responsible for Process and Analytical Development, as well as tech transfer of processes and methods to a newly built state-of-the-art cGMP facility. Before Lyell, Bruce served as the Sr. Director of the Therapeutic Products Program at Fred Hutchinson Cancer Research Center (FHCRC), where he led GMP manufacturing of cell and gene therapy products. He supported more than 15 active clinical programs and contributed to the filing of 6 INDs for various cell therapy programs. Bruce also spent nearly 10 years at Pfizer in the Pharmaceutical Sciences division where he gained expertise in analytical and process development.
Bruce received his B.A. in Biology, an M.S. in Biochemistry from The Ohio State University and Ph.D. in Microbiology and Immunology from the University of Louisville.